KIT codon 558 insertions in gastrointestinal stromal tumors. Analysis of 17 rare KIT mutants.

[1]  N. Pandis,et al.  KIT exon 11 codon 557/558 deletion/insertion mutations define a subset of gastrointestinal stromal tumors with malignant potential. , 2008, World journal of gastroenterology.

[2]  J. Lasota,et al.  KIT exon 11 deletion-inversions represent complex mutations in gastrointestinal stromal tumors. , 2007, Cancer genetics and cytogenetics.

[3]  J. Lasota,et al.  Mutations in gastrointestinal stromal tumors – a population‐based study from Northern Norway , 2007, Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS).

[4]  S. Hirota,et al.  Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation , 2007, Laboratory Investigation.

[5]  A. Hartmann,et al.  Minute Gastric Sclerosing Stromal Tumors (GIST Tumorlets) Are Common in Adults and Frequently Show c-KIT Mutations , 2007, The American journal of surgical pathology.

[6]  J. Fletcher,et al.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Blay,et al.  KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.

[8]  J. Lasota,et al.  KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). , 2006, Seminars in diagnostic pathology.

[9]  J. Lasota,et al.  Gastrointestinal stromal tumors: pathology and prognosis at different sites. , 2006, Seminars in diagnostic pathology.

[10]  H. Joensuu,et al.  Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. , 2006, Gastroenterology.

[11]  L. Sobin,et al.  Gastrointestinal Stromal Tumors of the Jejunum and Ileum: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 906 Cases Before Imatinib With Long-term Follow-up , 2006, The American journal of surgical pathology.

[12]  A. Llombart‐Bosch,et al.  Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Rossi,et al.  The value of c-kit mutational analysis in a cytokeratin positive gastrointestinal stromal tumour , 2005, Journal of Clinical Pathology.

[14]  Michael Zuker,et al.  DINAMelt web server for nucleic acid melting prediction , 2005, Nucleic Acids Res..

[15]  C. Antonescu,et al.  Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.

[16]  L. Sobin,et al.  Gastrointestinal Stromal Tumors of the Stomach: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 1765 Cases With Long-term Follow-up , 2005, The American journal of surgical pathology.

[17]  Y. Kitamura,et al.  Oncogenic protein tyrosine kinases , 2004, Cellular and Molecular Life Sciences CMLS.

[18]  Tina Hernandez-Boussard,et al.  Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles , 2004, Oncogene.

[19]  A. Hagemeijer,et al.  Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site , 2004, Modern Pathology.

[20]  E. Wardelmann,et al.  Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. , 2004, The Journal of molecular diagnostics : JMD.

[21]  L. Sobin,et al.  A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential , 2004, Laboratory Investigation.

[22]  R. Schneider-Stock,et al.  KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. , 2003, Human pathology.

[23]  S. Steigen,et al.  Gastrointestinal Stromal Tumors with Internal Tandem Duplications in 3′ End of KIT Juxtamembrane Domain Occur Predominantly in Stomach and Generally Seem to Have a Favorable Course , 2003, Modern Pathology.

[24]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Wardelmann,et al.  Deletion of Trp‐557 and Lys‐558 in the juxtamembrane domain of the c‐kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors , 2003, International journal of cancer.

[26]  M. Ladanyi,et al.  Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[28]  G. Demetri.  Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). , 2002, European journal of cancer.

[29]  Tony Pawson,et al.  Regulation and targets of receptor tyrosine kinases. , 2002, European journal of cancer.

[30]  U. Lendahl,et al.  Patterns of nestin and other intermediate filament expression distinguish between gastrointestinal stromal tumors, leiomyomas and schwannomas * , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[31]  E. Wardelmann,et al.  c-kit Mutations in Gastrointestinal Stromal Tumors Occur Preferentially in the Spindle Rather Than in the Epithelioid Cell Variant , 2002, Modern Pathology.

[32]  C. J. Chen,et al.  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.

[33]  T. Jacks,et al.  STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.

[34]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[35]  J. Huizinga,et al.  Gastrointestinal peristalsis: Joint action of enteric nerves, smooth muscle, and interstitial cells of Cajal , 1999, Microscopy research and technique.

[36]  S. Hirota,et al.  Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. , 1999, Cancer research.

[37]  L. Kindblom,et al.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. , 1998, The American journal of pathology.

[38]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[39]  M. Jasin,et al.  Palindrome resolution and recombination in the mammalian germ line , 1997, Molecular and cellular biology.

[40]  H. Maki.  Origins of spontaneous mutations: specificity and directionality of base-substitution, frameshift, and sequence-substitution mutageneses. , 2002, Annual review of genetics.

[41]  P. Åman,et al.  The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. , 2002, The American journal of pathology.